Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H25NO2 |
Molecular Weight | 311.418 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=JGOAIQNSOGZNBX-UHFFFAOYSA-N
InChI=1S/C20H25NO2/c1-3-21(4-2)15-16-23-20(22)19(17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,19H,3-4,15-16H2,1-2H3
Molecular Formula | C20H25NO2 |
Molecular Weight | 311.418 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Adiphenine is a ternary amino ligand. It is used as a local anesthetic that reduces the frequency of acetylcholine-induced single-channel currents. It was originally introduced as a spasmolytic agent. Adiphenine reduced the muscle tone of the gastrointestinal tract, bile duct and gallbladder, bronchi, bladder. It affects the tone of the muscles of the eye, causing the pupil dilated (mydriasis), increased intraocular pressure, and paralysis of accommodation. Influences on the cardiovascular system, causing tachycardia and improving AV-conduction. Adiphenine side effects are: nausea, vomiting, heartburn, dizziness, headache. Adiphenine has not been widely used clinically.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6112821
Curator's Comment: Known to be CNS penetrant in mice and rats. Human data not available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3137264 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19422391 |
|||
Target ID: CHEMBL1907609 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3404446 |
198.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Trasentine Approved UseAdiphenine is indicated for the treatment of spasms of smooth muscles of the digestive tract, bile ducts, bronchi. |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19422391 |
Primary | Trasentine Approved UseUnknown |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator​
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [Activation >10 uM] | ||||
no [Activation >10 uM] | ||||
no [Activation >10 uM] | ||||
yes [Activation 5.01187 uM] | ||||
yes [Activation 5.01187 uM] | ||||
yes [IC50 158.4 uM] | ||||
yes [Inhibition 10 uM] | ||||
yes [Inhibition 10 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
By the way, doctor. I've been taking Paxil for depression for about six months. Although it's helped my symptoms of depression, I've lost interest in sex. Aside from stopping the medication, is there any way to regain my sexual function? | 2001 Feb |
|
Receptor protection studies to characterize neuronal nicotinic receptors: tubocurarine prevents alkylation of adrenal nicotinic receptors. | 2001 Feb 9 |
|
Paxil and self-scratching. | 2001 Jan |
|
New use for Paxil approved. | 2001 Jul-Aug |
|
Serotonin reuptake inhibitor (Paxil) does not prevent the vasovagal reaction associated with carotid sinus massage and/or lower body negative pressure in healthy volunteers. | 2002 Sep 17 |
|
Concerns about Paxil for children. | 2003 Sep-Oct |
|
A taxpayer-funded clinical trials registry and results database. | 2004 Dec |
|
Antidepressant medication use among First Nations peoples residing within British Columbia. | 2004 Nov 5 |
|
Acute and chronic toxicity of five selective serotonin reuptake inhibitors in Ceriodaphnia dubia. | 2004 Sep |
|
[Clinical effects of paxil in poststroke rehabilitation]. | 2005 |
|
Serotonin and depression: a disconnect between the advertisements and the scientific literature. | 2005 Dec |
|
Medicine as a corporate enterprise, patient welfare centered profession, or patient welfare centered professional enterprise? | 2005 Nov |
|
Paxil: part of the process. | 2006 Apr |
|
Disease mongering in drug promotion: do governments have a regulatory role? | 2006 Apr |
|
Rare case of serotonin syndrome with therapeutic doses of paroxetine. | 2006 Nov-Dec |
|
Effect of generic-only drug benefits on seniors' medication use and financial burden. | 2006 Sep |
|
The SSRI trials in children: disturbing implications for academic medicine. | 2006 Spring |
|
Patterns of prescription and self-medication for treating primary dysmenorrhea in a Mexican population. | 2007 |
|
Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. | 2007 Dec |
|
Generic entry, reformulations and promotion of SSRIs in the US. | 2008 |
|
Paroxetine. | 2008 Apr |
|
Trial registration for public trust: making the case for medical devices. | 2008 Jan |
|
Nutritional therapies for mental disorders. | 2008 Jan 21 |
|
[The anxyolytic effect of mild hypobaric hypoxia in a model of post-traumatic stress disorder in rats]. | 2008 Jul-Aug |
|
Sequestered evidence and the distortion of clinical practice guidelines. | 2009 Spring |
|
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project. | 2010 |
|
Legal remedies for medical ghostwriting: imposing fraud liability on guest authors of ghostwritten articles. | 2010 Aug |
|
The chemical basis of pharmacology. | 2010 Dec 7 |
|
Of sophists and spin-doctors: industry-sponsored ghostwriting and the crisis of academic medicine. | 2010 Jan |
|
Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors. | 2010 Nov 17 |
|
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. | 2015 Jan 5 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.piluli.kharkov.ua/drugs/drug/195/
50-100 mg 2-3-4 times per day. Course of treatment - 3-4 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19422391
Adiphenine decreased the frequency of ACh-induced single-channel currents. Adiphenine decreased cluster duration (36-fold at 100 uM x L(-1)). Preincubation with adiphenine did not change amplitude but increased the decay rate (IC(50)= 15 uM x L(-1)).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:55:52 GMT 2023
by
admin
on
Sat Dec 16 16:55:52 GMT 2023
|
Record UNII |
YKG6OR043Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29698
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m1419
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
YKG6OR043Q
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | |||
|
3282
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | |||
|
333
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | RxNorm | ||
|
2031
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | |||
|
100000087702
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | |||
|
Adiphenine
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | |||
|
DTXSID0022561
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | |||
|
C76456
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | |||
|
C084829
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | |||
|
200-599-0
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | |||
|
CHEMBL353846
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | |||
|
94
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | |||
|
SUB05272MIG
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | |||
|
2715
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY | |||
|
64-95-9
Created by
admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |